Goldman Sachs says Merck KGaA still has room to run

A smaller target, not a broken thesis

Goldman Sachs shaved its price target on Merck KGaA to €147, but it didn’t kick the stock out of the Buy club. So no, this isn’t a dramatic “run for the hills” moment — more like Wall Street taking a slightly more cautious lap around the same name.

Why the mood changed

The fresh note leans on the idea that growth is still a bit restrained, especially when you zoom out and ask how fast Merck KGaA can really re-accelerate. That’s the whole game here: if the pharma business can get its groove back, the stock has room for a re-rating. If not, you’re left with a decent company that feels a little stuck in second gear.

What investors should watch

This matters because analyst calls can shape sentiment fast, especially when a stock is already sitting in the “prove it” bucket. The market is basically waiting for a couple of things:

• a clearer growth story in pharma
• better confidence that the pipeline can support it
• less hand-wringing about whether the current pace is good enough

Big picture

The takeaway is pretty simple: Goldman didn’t turn bearish, but it did tap the brakes. For investors, that’s a reminder that Merck KGaA still needs to show the market something sturdier than polite optimism if it wants a real rerating.